<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92280">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01741454</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0279</org_study_id>
    <nct_id>NCT01741454</nct_id>
  </id_info>
  <brief_title>Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction</brief_title>
  <official_title>Combination Versus Monotherapy With Alpha Blocker and Anticholinergics to Relieve Urinary Stent Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether combination therapy with Tolterodine ER
      and Tamsulosin is more effective than monotherapy with tamsulosin alone in reducing stent
      symptoms.

      The investigators hope to show that the addition of Tolterodine ER to Tamsulosin will
      provided added benefits in reducing stent symptoms in patients who have had unilateral
      placement of a ureteral stent.

      The investigators hypothesize that combination therapy with tamsulosin and tolterodine ER
      will yield greater symptom relief than tamsulosin alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to show that the addition of Tolterodine ER to Tamsulosin will provide
      added benefits in ameliorating stent related symptoms in patients who have had unilateral
      placement of a ureteral stent for urolithiasis.  This objective will be assessed by
      determining the mean difference in the urinary symptom index domain of the Urinary Stent
      Symptom Questionnaire, which is a validated tool used to assess stent symptoms1.  The
      investigators felt that a 15% further decrease in the index score in the experimental group,
      compared to the control group would represent a clinically significant improvement in
      urinary symptoms, based on the prior studies evaluating lower urinary tract symptoms in
      patients with stents. The investigators hypothesize that combination therapy with Tamsulosin
      and Tolterodine ER will yield greater symptom relief than tamsulosin alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ureteral stent symptom questionnaire score</measure>
    <time_frame>Up to 24 hours prior to stent insertion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ureteral stent symptom questionnaire score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ureteral stent symptom questionnaire score</measure>
    <time_frame>42-48 hours post-stent insertion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ureteral stent symptom questionnaire score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ureteral stent symptom questionnaire score</measure>
    <time_frame>5 days post-stent insertion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ureteral stent symptom questionnaire score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ureteral stent symptom questionnaire score</measure>
    <time_frame>Up to 24 hours after stent removal.  Removal will occur 5 to 7 days after insertion.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ureteral stent symptom questionnaire score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Ureteral Obstruction</condition>
  <arm_group>
    <arm_group_label>Tamsulosin plus placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin plus Tolterodine ER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>0.4 mg by mouth once per day.</description>
    <arm_group_label>Tamsulosin plus placebo</arm_group_label>
    <arm_group_label>Tamsulosin plus Tolterodine ER</arm_group_label>
    <other_name>Flomax (TM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine ER</intervention_name>
    <description>4 mg by mouth once a day.</description>
    <arm_group_label>Tamsulosin plus Tolterodine ER</arm_group_label>
    <other_name>Detrol (TM)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with unilateral ureteral stent placement for urolithiasis

        Exclusion Criteria:

          1. Pre-existing lower urinary tract symptoms

          2. Active urinary tract infection

          3. Contraindication to anticholinergic medication

               1. Prior hypersensitivity or allergy to tolterodine

               2. Patients with severe hepatic impairment (Child-Pugh Class C)

               3. Patients with uncontrolled close (narrow) angle glaucoma

               4. Patients with urinary retention

          4. Current anticholinergic use

          5. Chronic pelvic pain syndromes (e.g. acute/chronic prostatitis, interstitial cystitis)

          6. Pregnant females

          7. Under 18 years of age

          8. Prior hypersensitivity or allergy to tolterodine

          9. Patients with severe hepatic impairment (Child-Pugh Class C)

         10. Patients with uncontrolled close (narrow) angle glaucoma

         11. Patients with urinary retention

         12. Unable to provide informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Nakada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicky Kurtzweil, JD</last_name>
    <phone>(608) 262-9383</phone>
    <email>kurtzweil@surgery.wisc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren Howard, MPH</last_name>
    <phone>(608) 265-6648</phone>
    <email>howard@surgery.wisc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vista Medical Center East</name>
      <address>
        <city>Waukegan</city>
        <state>Illinois</state>
        <zip>60085</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sutchin Patel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sutchin Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicky Kurtzweil, JD</last_name>
      <phone>608-262-9383</phone>
      <email>kurtzweil@surgery.wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Howard, MPH</last_name>
      <phone>608-265-6648</phone>
      <email>howard@surgery.wisc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Nakada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meriter Health Services</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Paolone, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Paolone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winnipeg Health Sciences Center</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Turki Al-Essawi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Turki Al-Essawi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 18, 2013</lastchanged_date>
  <firstreceived_date>November 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tolterodine</keyword>
  <keyword>Tamsulosin</keyword>
  <keyword>Ureteral Obstruction</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ureteral Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholinergic Antagonists</mesh_term>
    <mesh_term>Tolterodine</mesh_term>
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
